Overview
Background
Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. In 2003 he moved to Brisbane, and works as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying immunity and identification of novel biomarkers in lymphoma, with continuous NHMRC funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Diamantina Institute, and was appointed Diamantina Cancer Program Head in 2016. In 2018 to current, he moved to Mater Research, where he is Executive Director, as well Director of MRI-UQ.
Availability
- Professor Maher Gandhi is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Medicine Surgery, University of Aberdeen
- Doctor of Philosophy, University of Cambridge
Research interests
-
Lymphoma
-
Immunotherapy
-
Biomarkers
Research impacts
The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. We utilise a broad range of approaches including genomics, molecular and cellular biology techniques and functional immunoassays. Several of our studies are linked with the Australasian Leukaemia and Lymphoma Group.
The Mater Foundation, the Leukaemia Foundation, and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.
Works
Search Professor Maher Gandhi’s works on UQ eSpace
2019
Journal Article
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458
2019
Journal Article
The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma
Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274
2019
Journal Article
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
Barraclough, Allison, Alzahrani, Musa, Ettrup, Marianne Schmidt, Bishton, Mark, van Vliet, Chris, Farinha, Pedro, Gould, Clare, Birch, Simone, Sehn, Laurie H., Sovani, Vishakha, Ward, Mitchell Steven, Augustson, Bradley, Biccler, Jorne, Connors, Joseph M., Scott, David W., Gandhi, Maher K., Savage, Kerry J., El-Galaly, Tarec, Villa, Diego and Cheah, Chan Yoon (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 3 (13), 2013-2021. doi: 10.1182/bloodadvances.2019000251
2019
Journal Article
Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions
Stannard, Kimberley A., Lemoine, Sébastien, Waterhouse, Nigel J., Vari, Frank, Chatenoud, Lucienne, Gandhi, Maher K., Martinet, Ludovic, Smyth, Mark J. and Guillerey, Camille (2019). Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 3 (11), 1681-1694. doi: 10.1182/bloodadvances.2018030676
2019
Conference Publication
EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy
Gandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629
2019
Journal Article
Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions
Lees, Charlotte, Keane, Colm, Gandhi, Maher K. and Gunawardana, Jay (2019). Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. British Journal of Haematology, 185 (1), 25-41. doi: 10.1111/bjh.15778
2019
Journal Article
Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies
Law, Soi Cheng, Haigh, Oscar L., Walpole, Carina M., Keane, Colm, Miles, John, Gandhi, Maher K., Radford, Kristen J. and Steptoe, Raymond J. (2019). Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies. Journal of Immunological Methods, 465, 72-76. doi: 10.1016/j.jim.2018.12.002
2019
Conference Publication
B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL
Gould, Clare, Keane, Colm, Murigneux, Valentine, Oey, Harald, Ellis, Jonathan, Birch, Simone, Gunawardana, Jay, Talaulikar, Dipti, Hertzberg, Mark S., Jones, Kimberley and Gandhi, Maher K. (2019). B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL. ASH Annual Meeting, Orlando, FL, United States, 7-10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-126537
2018
Journal Article
Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker
Sina, Abu Ali Ibn, Carrascosa, Laura G., Liang, Ziyu, Grewal, Yadveer S., Wardiana, Andri, Shiddiky, Muhammad J. A., Gardiner, Robert A., Samaratunga, Hemamali, Gandhi, Maher K., Scott, Rodney J., Korbie, Darren and Trau, Matt (2018). Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 9 (1) 4915, 4915. doi: 10.1038/s41467-018-07214-w
2018
Conference Publication
A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial
Abro, Emad Uddin, Law, Soi C., Keane, Colm, Birch, Simone, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Johnson, Peter, Trotman, Judith, Berkahn, Leanne, Fulham, Michael, Anderson, Richard A., Saunderson, Anne L., Gunawardana, Jay, Cross, Donna, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Law, W. P., Gill, Devinder and Gandhi, Maher K. (2018). A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial. 60th ASH Annual Meeting, San Diego, CA United States, 1-4 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-112008
2018
Journal Article
Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma
Cui, Qingyan, Vari, Frank, Cristino, Alexandre S., Salomon, Carlos, Rice, Gregory E., Sabdia, Muhammed B., Guanzon, Dominic, Palma, Carlos, Mathew, Marina, Talaulikar, Dipti, Jain, Sanjiv, Han, Erica, Hertzberg, Mark S., Gould, Clare, Crooks, Pauline, Thillaiyampalam, Gayathri, Keane, Colm and Gandhi, Maher K. (2018). Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma. Oncotarget, 9 (78), 34644-34657. doi: 10.18632/oncotarget.26141
2018
Journal Article
A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival
Keane, Colm, Tobin, Joshua, Talaulikar, Dipti, Green, Michael, Crooks, Pauline, Jain, Sanjiv and Gandhi, Maher (2018). A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. OncoTarget, 9 (34), 23620-23627. doi: 10.18632/oncotarget.25306
2018
Conference Publication
Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis
Keane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830
2018
Conference Publication
The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma
Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826
2018
Conference Publication
Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance
Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David C., Dunduru, Chengetai, Bell, Stephen, Gallo, James, Tsang, Erica, Tan, Xuan, Pearce, Jessica, Wong, Jonathan, Campbell, Robert, Tneh, Shao Yang, Shorten, Sophie, Ng, Melissa Liet Hing, Darch, Jacob, Cochrane, Tara, Tam, Constantine S., Abro, Emad Uddin, Hawkes, Eliza, Hodges, Georgina, Talaulikar, Dipti, Gilbertson, Michael P., Johnson, Anna, Kansara, Roopesh R., Villa, Diego, Savage, Kerry J., Morris, Kirk Lachlan ... Hapgood, Greg (2018). Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114097
2018
Journal Article
B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity
McKee, Sara J., Tuong, Zewen K., Kobayashi, Takumi, Doff, Brianna L., Soon, Megan S. F ., Nissen, Michael, Lam, Pui Yeng, Keane, Colm, Vari, Frank, Moi, Davide, Mazzieri, Roberta, Leggatt, Graham, Gandhi, Maher K. and Mattarollo, Stephen R. (2018). B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 7 (2) e1393599, e1393599. doi: 10.1080/2162402X.2017.1393599
2018
Conference Publication
The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma
Gunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836
2017
Conference Publication
The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma
Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh , Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728
2017
Journal Article
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14
Hertzberg, Mark, Gandhi, Maher K. , Trotman, Judith, Butcher, Belinda, Taper, John, Johnston, Amanda, Gill, Devinder, Ho, Shir-Jing, Cull, Gavin, Fay, Ketih, Chong, Geoff, Grigg, Andrew, Lewis, Ian D. , Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Kannourakis, George, Watson, Anne-Marie, Warburton, Pauline, Wirth, Andrew, Seymour, John F. , Hofman, Michael S. and Hicks, Rodney J. (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102 (2), 356-363. doi: 10.3324/haematol.2016.154039
2017
Conference Publication
The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial
Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.
Funding
Supervision
Availability
- Professor Maher Gandhi is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Personalised therapy for lymphoma
Principal Advisor
Other advisors: Honorary Professor Kristen Radford
-
Doctor Philosophy
Metabolic Reprogramming of Malignant B-cells Impairs Immune-Fitness of Intratumoral T-Cells in Follicular Lymphoma
Principal Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law
-
Doctor Philosophy
Impact of genetics upon the tumour microenvironment in Follicular Lymphoma
Principal Advisor
Other advisors: Dr Joshua Tobin, Dr Soi Law, Associate Professor Colm Keane
-
Doctor Philosophy
Investigations in the development of cord blood derived, GMP grade cellular immunotherapies
Associate Advisor
Other advisors: Honorary Professor Kristen Radford
-
Doctor Philosophy
Development of novel vaccines for cancer immunotherapy
Associate Advisor
Other advisors: Dr Kelvin Tuong, Honorary Professor Kristen Radford
Completed supervision
-
2022
Doctor Philosophy
A Comprehensive Study of Intratumoural T-cells in Follicular Lymphoma
Principal Advisor
Other advisors: Dr Soi Law, Associate Professor Colm Keane
-
2021
Doctor Philosophy
Clinical and Prognostic Tools to Improve Frontline Management Strategies in Follicular Lymphoma
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
2020
Doctor Philosophy
The impact of deficient antigen presentation on the tumour microenvironment of diffuse large B cell lymphoma
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
-
2019
Doctor Philosophy
A LABORATORY STUDY OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
2017
Master Philosophy
An in vitro model for the generation of highly immunosuppressive CD163hi monocytic myeloid-derived suppressor cells (moMDSC) to assist in the development of new immunotherapies for aggressive lymphoma
Principal Advisor
-
2016
Master Philosophy
Killer cell Immunoglobulin-like Receptors in Immune Thrombocytopenia (ITP)
Principal Advisor
-
2013
Doctor Philosophy
Novel strategies for monitoring, treating and preventing Epstein Barr virus-associated Lymphomas
Principal Advisor
-
2020
Doctor Philosophy
Characterising miRNA - gene network associated with natural killer cell activation
Associate Advisor
Other advisors: Dr Soi Law
-
2019
Doctor Philosophy
Deciphering the structure and function of class I cytokine receptors: GHR and GP130
Associate Advisor
Other advisors: Associate Professor Andrew Brooks
-
2013
Doctor Philosophy
IRE1-mediated splicing of xbp1 in Natural Killer cells
Associate Advisor
Media
Enquiries
Contact Professor Maher Gandhi directly for media enquiries about:
- Biomarkers
- Immunotherapy
- Lymphoma
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: